128 related articles for article (PubMed ID: 16120621)
1. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Ishii H; Furuse J; Kinoshita T; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Nakachi K; Suzuki E; Yoshino M
Jpn J Clin Oncol; 2005 Sep; 35(9):526-30. PubMed ID: 16120621
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
3. Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care.
Ragnarson-Tennvall G; Wilking N
Pharmacoeconomics; 1999 Apr; 15(4):377-84. PubMed ID: 10537956
[TBL] [Abstract][Full Text] [Related]
4. Impact of gemcitabine on the treatment of metastatic pancreatic cancer.
Ishii H; Furuse J; Nagase M; Yoshino M
J Gastroenterol Hepatol; 2005 Jan; 20(1):62-6. PubMed ID: 15610448
[TBL] [Abstract][Full Text] [Related]
5. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
Bansback N; Ward S; Karnon J
Eur J Health Econ; 2004 Jun; 5(2):188-9. PubMed ID: 15452756
[No Abstract] [Full Text] [Related]
8. The economic burden of metastatic pancreatic cancer.
Malangone-Monaco E; Doleh Y; Cole A; Noxon V; Antico G; Pishvaian MJ
Pancreatology; 2020 Oct; 20(7):1434-1441. PubMed ID: 32967794
[TBL] [Abstract][Full Text] [Related]
9. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Krzyzanowska MK; Earle CC; Kuntz KM; Weeks JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):211-8. PubMed ID: 17189071
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
11. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
12. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of radiotherapy for locally advanced pancreatic cancer.
Sawaki A; Hoki N; Ito S; Matsumoto K; Mizuno N; Hara K; Takagi T; Kobayashi Y; Sawai Y; Kawai H; Tajika M; Nakamura T; Yamao K
J Gastroenterol; 2009; 44(12):1209-14. PubMed ID: 19705054
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
[TBL] [Abstract][Full Text] [Related]
15. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Oztop I; Yilmaz U; Yavuzsen T; Yaren A; Tarhan O; Sagol O; Coker A; Alakavuklar M
Chemotherapy; 2004 Jun; 50(3):127-32. PubMed ID: 15282439
[TBL] [Abstract][Full Text] [Related]
17. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
[TBL] [Abstract][Full Text] [Related]
18. Personal experience in advanced pancreatic cancer: retrospective analysis on the use of 5-fluorouracil or gemcitabine.
Martinelli B; Pigni A; Fagnoni E; Chini C; Vallini I; Pinotti G
Dig Liver Dis; 2001; 33(6):503. PubMed ID: 11572580
[No Abstract] [Full Text] [Related]
19. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Ueno H; Ioka T; Ikeda M; Ohkawa S; Yanagimoto H; Boku N; Fukutomi A; Sugimori K; Baba H; Yamao K; Shimamura T; Sho M; Kitano M; Cheng AL; Mizumoto K; Chen JS; Furuse J; Funakoshi A; Hatori T; Yamaguchi T; Egawa S; Sato A; Ohashi Y; Okusaka T; Tanaka M
J Clin Oncol; 2013 May; 31(13):1640-8. PubMed ID: 23547081
[TBL] [Abstract][Full Text] [Related]
20. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]